Literature DB >> 15451839

Antiarrhythmic drugs for atrial fibrillation: Do we need better use, better drugs or a randomized trial of ablation as primary therapy?

Stanley Nattel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15451839      PMCID： PMC517862          DOI： 10.1503/cmaj.1040853

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  19 in total

Review 1.  Cardiac ultrarapid delayed rectifiers: a novel potassium current family o f functional similarity and molecular diversity.

Authors:  S Nattel; L Yue; Z Wang
Journal:  Cell Physiol Biochem       Date:  1999

2.  Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis.

Authors:  M A Wood; C Brown-Mahoney; G N Kay; K A Ellenbogen
Journal:  Circulation       Date:  2000-03-14       Impact factor: 29.690

3.  A comparison of rate control and rhythm control in patients with atrial fibrillation.

Authors:  D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

4.  Atrial electroanatomic remodeling after circumferential radiofrequency pulmonary vein ablation: efficacy of an anatomic approach in a large cohort of patients with atrial fibrillation.

Authors:  C Pappone; G Oreto; S Rosanio; G Vicedomini; M Tocchi; F Gugliotta; A Salvati; C Dicandia; M P Calabrò; P Mazzone; E Ficarra; C Di Gioia; S Gulletta; S Nardi; V Santinelli; S Benussi; O Alfieri
Journal:  Circulation       Date:  2001-11-20       Impact factor: 29.690

5.  Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure.

Authors:  D Li; K Shinagawa; L Pang; T K Leung; S Cardin; Z Wang; S Nattel
Journal:  Circulation       Date:  2001-11-20       Impact factor: 29.690

6.  The T-type Ca(2+) channel blocker mibefradil prevents the development of a substrate for atrial fibrillation by tachycardia-induced atrial remodeling in dogs.

Authors:  S Fareh; A Bénardeau; B Thibault; S Nattel
Journal:  Circulation       Date:  1999-11-23       Impact factor: 29.690

7.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.

Authors:  O D Pedersen; H Bagger; L Kober; C Torp-Pedersen
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

8.  Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study.

Authors:  Antonio H Madrid; Manuel G Bueno; Jose M G Rebollo; Irene Marín; Gonzalo Peña; Enrique Bernal; Aníbal Rodriguez; Lucas Cano; José M Cano; Pedro Cabeza; Concepción Moro
Journal:  Circulation       Date:  2002-07-16       Impact factor: 29.690

Review 9.  Electrical, contractile and structural remodeling during atrial fibrillation.

Authors:  Maurits Allessie; Jannie Ausma; Ulrich Schotten
Journal:  Cardiovasc Res       Date:  2002-05       Impact factor: 10.787

Review 10.  Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management?

Authors:  Stanley Nattel
Journal:  Cardiovasc Res       Date:  2002-05       Impact factor: 10.787
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.